(MedPage Today) — The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable gastric or gastroesophageal junction cancer, the agency announced on Tuesday.
Approval stipulates use of…
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/118746
Author :
Publish date : 2025-11-26 17:46:00
Copyright for syndicated content belongs to the linked Source.
